Source:http://linkedlifedata.com/resource/pubmed/id/15729371
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2005-4-21
|
| pubmed:abstractText |
Antiangiogenic immunotherapy benefits from targeting antigens expressed on genetically stable endothelial cells and represents a novel modality for cancer treatment. Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2, also known as flk1 in mouse) mediated VEGF signaling is the key rate-limiting step in angiogenesis. Blockade of the flk1 signaling pathway can significantly inhibit tumor cell-induced angiogenesis and lead to inhibition of tumor metastasis. Interferon-gamma (IFN-gamma) is a pleiotropic cytokine, which plays an important role in cell-mediated immunity. In this study, we tested the hypothesis that immunization of mice with soluble flk1 (sflk1) and IFN-gamma fusion gene-transfected dendritic cells (DC-sflk1-IFN-gamma) would induce a potent CTL response to flk1, leading to an inhibition of tumor-induced angiogenesis and metastasis. Our data show that immunization of mice with sflk1 gene-modified DC (DC-sflk1) could induce a CTL response to flk1, leading to profound inhibition of tumor-cell-induced angiogenesis and metastasis. However, more striking antimetastatic effects were achieved through induction of enhanced CTL response to flk1 and augmented inhibition of angiogenesis when mice were immunized with DC-sflk1-IFN-gamma. In vivo T-cell subset depletion experiments showed that CD8(+) T cells were mainly responsible for this antimetastatic effect. Our data extend the notion that DC-based active antiangiogenic immunotherapy is an effective modality for cancer treatment, and show that the antitumor efficacy of this strategy can be improved by combination with DC-based cytokine immunotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0969-7128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
742-50
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:15729371-Animals,
pubmed-meshheading:15729371-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15729371-Cancer Vaccines,
pubmed-meshheading:15729371-Carcinoma, Lewis Lung,
pubmed-meshheading:15729371-Cytotoxicity, Immunologic,
pubmed-meshheading:15729371-Dendritic Cells,
pubmed-meshheading:15729371-Electroporation,
pubmed-meshheading:15729371-Female,
pubmed-meshheading:15729371-Immunity, Cellular,
pubmed-meshheading:15729371-Immunization,
pubmed-meshheading:15729371-Interferon-gamma,
pubmed-meshheading:15729371-Melanoma, Experimental,
pubmed-meshheading:15729371-Mice,
pubmed-meshheading:15729371-Mice, Inbred C57BL,
pubmed-meshheading:15729371-Neoplasm Metastasis,
pubmed-meshheading:15729371-Neoplasms, Experimental,
pubmed-meshheading:15729371-Neovascularization, Pathologic,
pubmed-meshheading:15729371-Plasmids,
pubmed-meshheading:15729371-Transfection,
pubmed-meshheading:15729371-Vaccines, DNA,
pubmed-meshheading:15729371-Vascular Endothelial Growth Factor Receptor-2
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
|
| pubmed:affiliation |
Institute of Immunology, Zhejiang University, Hangzhou, People's Republic of China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|